Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track RDY with free AI briefings, catalyst countdowns, and dilution alerts.

RDY · DR REDDYS LABORATORIES LTD

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$76.2B Cash on Hand
CF+ Cash Runway
Follow RDY by email Get an email when RDY reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RDY, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Active01 Cream Common Warts Phase 2 · NCT02798419 Completed
DFD05 Cream Common Warts Phase 2 · NCT02798419 Completed
Denileukin Diftitox (E7777) Epithelial Ovarian Cancer Phase 1/2 · NCT05200559 Active not recruiting

Also used in these trials (approved or third-party drugs, not RDY's own candidates): Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RDY holds $76.2B in cash and short-term investments and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RDY files for a raise →

👥 Who Owns RDY

Insiders 0% Other 5%+ holders 13.6% Institutions (320 holders) 14.8% Public and other holders 71.6%
HolderTypeShares% of sharesAs of
K. Satish Reddy 5%+ holder (13D) 113,356,510 13.58% 2025-09-17

Share count 834,656,970 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full RDY picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RDY and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.